As dementia cases grow, biomarkers and new therapies key to unlocking treatment
Release Date:
Howard Fillit, founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation, shares his insights on the impact of financial investments driving these therapies.
As dementia cases grow, biomarkers and new therapies key to unlocking treatment